Haemonetics Co. (NYSE:HAE) is Royce & Associates LP’s 6th Largest Position

Royce & Associates LP lifted its holdings in Haemonetics Co. (NYSE:HAE) by 2.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,210,546 shares of the medical instruments supplier’s stock after acquiring an additional 30,868 shares during the period. Haemonetics accounts for about 0.9% of Royce & Associates LP’s portfolio, making the stock its 6th biggest holding. Royce & Associates LP owned approximately 2.37% of Haemonetics worth $97,304,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Quarry LP purchased a new position in shares of Haemonetics in the 2nd quarter worth $39,000. Covestor Ltd lifted its stake in shares of Haemonetics by 184.8% during the 1st quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier’s stock worth $58,000 after acquiring an additional 438 shares during the last quarter. Daiwa Securities Group Inc. purchased a new position in Haemonetics during the 2nd quarter valued at $82,000. Canada Pension Plan Investment Board bought a new position in Haemonetics in the 2nd quarter valued at $83,000. Finally, EntryPoint Capital LLC purchased a new stake in Haemonetics in the first quarter worth $86,000. Institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Down 1.1 %

Shares of NYSE HAE opened at $90.75 on Friday. Haemonetics Co. has a 52-week low of $70.25 and a 52-week high of $97.97. The company has a quick ratio of 2.09, a current ratio of 3.49 and a debt-to-equity ratio of 1.39. The company’s 50-day simple moving average is $76.90 and its 200-day simple moving average is $82.71. The firm has a market cap of $4.56 billion, a price-to-earnings ratio of 37.66, a price-to-earnings-growth ratio of 1.43 and a beta of 0.32.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $1.12 EPS for the quarter, beating the consensus estimate of $1.09 by $0.03. The firm had revenue of $345.50 million during the quarter, compared to the consensus estimate of $342.57 million. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The firm’s revenue was up 8.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.99 EPS. Equities analysts predict that Haemonetics Co. will post 4.59 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on HAE shares. Citigroup cut their price target on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating on the stock in a report on Thursday, August 22nd. CL King began coverage on Haemonetics in a report on Friday, September 13th. They issued a “buy” rating and a $116.00 price target for the company. JMP Securities restated a “market outperform” rating and set a $125.00 price objective on shares of Haemonetics in a report on Tuesday, August 13th. BTIG Research started coverage on Haemonetics in a research report on Tuesday, September 10th. They set a “buy” rating and a $112.00 price target on the stock. Finally, Bank of America assumed coverage on shares of Haemonetics in a research note on Wednesday, September 11th. They issued a “neutral” rating and a $85.00 price objective for the company. Three research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $107.88.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.